MOTS-c: Evidence, Mechanism & Metabolic regulation Research

MOTS-c (Mitochondrial-derived Peptide Two) is a 16-amino acid regulatory peptide encoded by the mitochondrial genome, specifically within the 12S ribosomal RNA gene. It was discovered in 2015 by Changhan David Lee and colleagues at the University of Southern California (PMID: 25738459). MOTS-c represents a novel class of signaling molecules called mitochondrial-derived peptides (MtDPs), which are generated from the mitochondrial genome and regulate cellular and organismal physiology. Unlike protein-derived hormones produced by the endocrine system, MOTS-c is synthesized from mitochondrial DNA and can translocate to the nucleus and other cellular compartments to exert regulatory effects. As of March 2026, MOTS-c remains a research compound without FDA approval or clinical application.

Lee et al. identified MOTS-c through a systematic screen of mitochondrial genome regions capable of encoding bioactive peptides. The peptide is derived from the 12S ribosomal RNA gene within the mitochondrial DNA, specifically from a sequence previously considered "non-coding." This discovery challenged the traditional view that mitochondrial DNA serves only structural roles in ribosomal function. MOTS-c is one of several mitochondrial-derived peptides, including humanin and MOTS-b, indicating that the mitochondrial genome encodes multiple regulatory molecules. The peptide undergoes post-translational modifications and can be cleaved from its primary transcript. MOTS-c is present in circulation in humans, with detectable serum levels that vary with age, metabolic state, and physical activity.

MOTS-c operates through AMPK pathway activation, the master metabolic regulator often called the "metabolic sensor." Under conditions of metabolic stress (energy depletion, hypoxia, exercise), MOTS-c translocates from mitochondria to the nucleus, where it coordinates gene expression changes. MOTS-c enhances AMPK phosphorylation and activation, downstream of which follows inhibition of mTOR and activation of catabolic pathways that improve energy availability. This mechanism mirrors cellular responses to caloric restriction and exercise. MOTS-c also appears to improve mitochondrial function and biogenesis through nuclear-mitochondrial signaling. The peptide may function as a nutrient sensor, translating nutritional status to systemic metabolic adjustments. The exact upstream receptor or direct binding target for MOTS-c activation of AMPK remains incompletely characterized, representing an area of active research.

Extensive mouse studies have demonstrated MOTS-c's metabolic benefits. Glucose homeostasis: MOTS-c administration improves fasting glucose levels and glucose tolerance in obese mice models. Insulin sensitivity: Both whole-body and tissue-specific insulin sensitivity improve with MOTS-c treatment. Obesity prevention: Mice receiving MOTS-c gain less weight on high-fat diets compared to controls, with improvements in adiposity and metabolic parameters. Energy expenditure: MOTS-c increases whole-body energy expenditure and thermogenesis. These effects are dose-dependent and reproducible across different mouse models of obesity and metabolic syndrome. Mechanistic studies confirm MOTS-c activates hepatic and skeletal muscle AMPK, consistent with systemic metabolic effects. Notably, MOTS-c appears to mimic physiological responses to endurance exercise, supporting the "exercise mimetic" hypothesis.

Human cross-sectional studies reveal important correlations with MOTS-c levels. Age-related decline: Serum MOTS-c concentrations progressively decrease with advancing age, consistent with age-related metabolic decline. Physical fitness: Individuals with higher aerobic fitness and greater physical activity levels show higher circulating MOTS-c. Metabolic health: MOTS-c levels correlate inversely with body mass index, fasting glucose, and markers of insulin resistance in observational studies. Longitudinal associations: Limited prospective data suggests baseline MOTS-c may predict metabolic outcomes, though causality cannot be established from observational data. These human associations support the hypothesis that MOTS-c participates in metabolic homeostasis and may be a biomarker of metabolic health, though they do not establish that MOTS-c supplementation would produce therapeutic benefits in humans.

A notable genetic finding links MOTS-c variants to exceptional longevity. A naturally occurring missense variant (m.1382A>C, resulting in K14Q amino acid change) was identified in a Japanese centenarian cohort with significantly higher prevalence in individuals with exceptional lifespans. Functional studies demonstrated that the K14Q variant enhances AMPK activation capacity compared to the wild-type peptide, suggesting improved metabolic signaling. This association provides intriguing evidence that MOTS-c function may contribute to healthy aging and longevity determination. However, this finding is from a population-specific cohort and replication in other ethnic groups and larger populations is needed. The variant is neither necessary nor sufficient for longevity—it represents one factor among the complex genetic and environmental determinants of lifespan.

As of March 2026, MOTS-c has not entered human clinical trials. No Phase 1, Phase 2, or Phase 3 studies have been conducted in patient populations. The compound remains in the preclinical research stage, with ongoing mechanistic studies, animal models, and exploratory human association research. Several academic groups continue investigating MOTS-c biology, but no pharmaceutical company has advanced it into formal clinical development pathways. For regulatory approval, MOTS-c would require demonstration of safety in human Phase 1 trials, followed by efficacy studies in relevant disease populations (obesity, type 2 diabetes, metabolic syndrome, age-related frailty). The lack of clinical data represents a significant knowledge gap compared to late-stage therapeutics like retatrutide. Potential clinical applications would likely target metabolic diseases and age-related conditions, but this remains speculative.

Several challenges impede translation of MOTS-c from bench to bedside. Bioavailability: As a 16-amino acid peptide, MOTS-c is susceptible to protease degradation and likely has poor oral bioavailability, necessitating parenteral administration if developed. Mechanism clarity: The upstream receptor or precise molecular target initiating MOTS-c signaling remains unidentified, limiting rational drug design and off-target risk assessment. Species translation: Efficacy in mouse models does not guarantee human efficacy or safety; metabolic responses often do not translate directly. Dosing and timing: Optimal dosing regimens, dosing frequency, and patient selection criteria are unknown. Long-term effects: Unknown whether sustained MOTS-c administration produces adaptation, tolerance, or unexpected adverse effects. Manufacturing: Synthesis and purification of bioactive MOTS-c peptide at pharmaceutical scale requires optimization.

Active research areas include mechanistic studies to identify MOTS-c's cellular receptor and refine understanding of nuclear translocation and gene regulatory functions. Structural biology efforts aim to optimize the peptide for enhanced potency, stability, or bioavailability. Extension studies in relevant disease models (obesity, type 2 diabetes, age-related frailty, sarcopenia) are exploring therapeutic potential beyond metabolic disorders. Development of synthetic peptide analogs with improved pharmacokinetic properties (e.g., PEGylation, cyclization, D-amino acid variants) may enhance translational prospects. Biomarker research seeks to establish whether serum MOTS-c levels predict metabolic outcomes and could guide patient selection for future therapeutics. Ultimate translation will require academic-industry partnerships to fund expensive clinical trial programs and manufacturing scale-up.